CRSP
CRISPR Therapeutics AG Healthcare - Gene Editing Investor Relations →
CRISPR Therapeutics AG (CRSP) closed at $46.24 as of 2026-03-20, trading 15.3% below its 200-week moving average of $54.61. This places CRSP in the extreme value zone. The stock is currently moving closer to the line, down from -10.8% last week. The 14-week RSI sits at 36, indicating neutral momentum.
Trading volume is running at 1.4x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.88 ratio) is neutral — neither side is clearly dominating.
Over the past 443 weeks of data, CRSP has crossed below its 200-week moving average 13 times. On average, these episodes lasted 16 weeks. Historically, investors who bought CRSP at the start of these episodes saw an average one-year return of +42.2%.
With a market cap of $4.4 billion, CRSP is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -30.2%. The stock trades at 2.3x book value.
Share count has increased 22.1% over three years, indicating dilution.
Over the past 8.6 years, a hypothetical investment of $100 in CRSP would have grown to $259, compared to $296 for the S&P 500. CRSP has returned 11.7% annualized vs 13.5% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 3 open-market purchases totaling $52,690,222. Notably, these purchases occurred while CRSP is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: CRSP vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CRSP Crosses Below the Line?
Across 12 historical episodes, buying CRSP when it crossed below its 200-week moving average produced an average return of +26.7% after 12 months (median -11.0%), compared to +9.2% for the S&P 500 over the same periods. 44% of those episodes were profitable after one year. After 24 months, the average return was +103.4% vs +30.0% for the index.
Each line shows $100 invested at the moment CRSP crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
CRSP has crossed below its 200-week MA 13 times with an average 1-year return of +42.2% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Sep 2017 | Oct 2017 | 1 | 1.5% | +148.2% | +158.8% |
| Nov 2017 | Nov 2017 | 1 | 4.1% | +108.4% | +165.0% |
| Dec 2018 | Jan 2019 | 3 | 26.9% | +199.4% | +103.4% |
| Feb 2019 | Feb 2019 | 1 | 2.4% | +72.2% | +52.2% |
| Nov 2021 | Dec 2021 | 2 | 5.0% | -22.2% | -34.0% |
| Jan 2022 | Jul 2022 | 26 | 35.9% | -30.2% | -31.7% |
| Jul 2022 | Aug 2022 | 1 | 1.1% | -24.1% | -38.3% |
| Aug 2022 | Feb 2024 | 78 | 51.5% | -29.8% | -32.6% |
| Mar 2024 | Jul 2025 | 71 | 48.8% | -42.3% | -41.4% |
| Jul 2025 | Sep 2025 | 6 | 7.4% | N/A | -17.6% |
| Nov 2025 | Dec 2025 | 4 | 8.7% | N/A | -16.1% |
| Dec 2025 | Feb 2026 | 8 | 10.8% | N/A | -14.0% |
| Mar 2026 | Ongoing | 2+ | 15.3% | Ongoing | -5.1% |
| Average | 16 | — | +42.2% | — |
Frequently Asked Questions
Is CRSP below its 200-week moving average?
Yes. As of 2026-03-20, CRISPR Therapeutics AG (CRSP) is trading 15.3% below its 200-week moving average of $54.61. The current price is $46.24.
What is CRSP's 200-week moving average price?
CRISPR Therapeutics AG's 200-week moving average is $54.61 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when CRSP drops below its 200-week moving average?
CRSP has crossed below its 200-week moving average 13 times in our data. On average, buying at that moment produced a one-year return of +42.2%. These dips have historically been decent entry points. These episodes lasted 16 weeks on average.
Is CRSP a good value right now?
Here's what our data says about CRSP as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 36. Free cash flow is currently negative. Return on equity is -30.2%. Price-to-book is 2.3x. This is not a buy or sell recommendation — always do your own research.
How does CRSP compare to the S&P 500?
Over the past 8.6 years, $100 invested in CRSP would have grown to $259, compared to $296 for the S&P 500. That's 11.7% annualized vs 13.5% for the index. CRSP has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20